Author: Yoo, D S; Lee, J H; Kim, S-C; Kim, J H
Title: Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Cord-id: v58c3522 Document date: 2021_3_3
ID: v58c3522
Snippet: Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases characterized by autoantibodies targeting BP230 and BP180. BP usually occurs in individuals over 70 years of age and shows a high mortality rate.1,2 In the meta-analysis, the 1-year mortality rate of BP patients was reported to be 23.5%.2 Rituximab, a monoclonal antibody targeting CD20, has shown high therapeutic efficacy in BP patients although the use of rituximab in BP is not approved in most countries including Eur
Document: Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases characterized by autoantibodies targeting BP230 and BP180. BP usually occurs in individuals over 70 years of age and shows a high mortality rate.1,2 In the meta-analysis, the 1-year mortality rate of BP patients was reported to be 23.5%.2 Rituximab, a monoclonal antibody targeting CD20, has shown high therapeutic efficacy in BP patients although the use of rituximab in BP is not approved in most countries including Europe and U.S.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date